NYSE - Kadmon Holdings, Inc.

График котировок Kadmon Holdings, Inc.


Добавить в список сравнения Добавить в список сравнения
Добавить в список отслеживания Добавить в список отслеживания
Добавить в портфель Добавить в портфель

Основные параметры

P/S 75.87
P/BV 8.78
EV/EBITDA -5.58
EBITDA -0.1006
Цена ао 3.66

Все параметры ⇨

Оценка

Недооценка

Название Значение Оценка
P/S 75.87 1
P/BV 8.78 1
P/E 0
EV/EBITDA -5.58 10

Эффективность

Название Значение Оценка
ROA, % -33.87 1
ROE, % -77.31 1

Дивиденды

Название Значение Оценка
Div yield, % 0
DSI 0 0

Долг

Название Значение Оценка
Долг/EBITDA 10

Импульс роста

Название Значение Оценка
Рост прибыли, % 0 0
Рост цены акции, % 0 0
Рост дивидендов, % 0 0

Основные владельцы

Институционалы Объем Доля, %
Perceptive Advisors LLC 15711334 9.16
SSGA Funds Management Inc 14049507 8.18
BlackRock Fund Advisors 13632958 7.93
Avidity Partners Management LP 9570000 5.57
Consonance Capital Management LP 7349621 4.28
Boxer Capital LLC 6205882 3.61
Woodline Partners LP 5878232 3.43
Vivo Capital, LLC 5817459 3.39
Great Point Partners LLC 4083909 2.38
Invesco Advisers, Inc. 2889179 1.68
Eversept Partners, LLC 2408885 1.4
Hauck & Aufhäuser Fund Services S.A. 1721803 1
Hauck & Aufhäuser Fund Services S.A. 1633803 0.95
Kennedy Capital Management 967195 0.56
Parkman Healthcare Partners LLC 934364 0.54
Knott David M 702000 0.41
Dafna Capital Management LLC 563564 0.33
RBC Global Asset Management Inc. 384079 0.22
Telemetry Investments, L.L.C. 362837 0.21
Gyon Technologies Capital Management, LP 308769 0.18
Invesco Capital Management LLC 297952 0.17
Reichmuth & Co Integrale Vermogensverwaltung AG 215946 0.13
Allianz Global Investors 143808 0.08
Puissance Capital Management LP 100184 0.06
Allianz Global Investors U.S. LLC 90365 0.05
Insight Advisors, LLC 18780 0.01

Похожие компании

Описание Kadmon Holdings, Inc.

Kadmon Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. Its lead product candidates include KD025, an orally administered selective inhibitor of the rho-associated coiled-coil kinase 2, which is in Phase II clinical trial for the treatment of chronic graft-versus-host and fibrotic diseases; KD045, an oral inhibitor of ROCK for the treatment of fibrotic diseases; and KD033, an anti-PD-L1\u002FIL-15 fusion protein for the treatment of cancer. The company also engages in developing Tesevatinib to treat autosomal dominant polycystic kidney disease; ribavirin, a nucleoside Inhibitor to treat hepatitis; and CLOVIQUE, a trientine hydrochloride capsules for the treatment of Wilson's disease. Kadmon Holdings, Inc. has strategic collaborations and license agreements with Nano Terra, Inc. and Dyax Corp. The company was founded in 2010 and is headquartered in New York, New York.